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ABSTRACT The effect of dextran sulfate (DS, 500,000 Mr)
and multilamellar vesicles (MLV) as liver blockade agents has been
investigated in mice. Intravenous injection of unlabeled MLV prior
to radioactive MLV caused moderate reduction in theliver uptake
and increased tibia, lung, and spleen uptake. More drastic dif-
ferences were observed with intraperitoneal injection of DS. When
tested in the range of 0-50 mg of DS per kg of body weight, max-
imal liver blockade occurred at a dose of 50 mg. By using 50 mg
of DS per kg, maximal liver blockade occurred at 12 hr after DS
injection. The liver blockade was temporary, ending within 48 hr.
The intraperitoneal route of injection for DS was more effective
for liver blockade than the intravenous route.
Since Bangham et al. (1) originally prepared phospholipid ves-
icles as model membranes, many investigators have recognized
their potential role as carriers of biologically active materials,
such as enzymes (2), chelators (3, 4), viral nucleic acids (5), an-
titumor drugs (6-11), antibiotics (12-14), immunogens (15-18),
and hormones (19). However, rapid liver uptake of intrave-
nously (i. v.) injected liposomes is a major obstacle to clinical use
of liposomes, because it does not allow the liposomes to reach
other important organs.
Approaches to overcome this problem have been. reported
by several laboratories: tumor-specific antibodies have been
bound to the surface of liposomes to direct them selectively
toward tumor cells in vivo (20), small liposomes have been shown
to stay in circulation longer (21), and temperature- and pH-sen-
sitive liposomes have been prepared that deliver their contents
to specific areas of the body (22, 23).
Alteration in the surface composition of liposomes has also
been used for selective delivery: liposomes with galactose-con-
taining surfaces are selectively delivered to the liver (24) and,
in particular, to the hepatocytes of the liver (11, 25, 26), li-
posomes with membrane insertion of either phosphatidylserine
(27, 28) or aminomannose are targeted selectively to macro-
phages (29), and liposomes that include sialogangliosides in the
membrane have somewhat reduced liver uptake (24).
Many of these approaches have improved the delivery of li-
posomes to specific organs but with little effect on the removal
of a large fraction of the circulating liposomes by the liver. There
have been some attempts to reduce liver uptake by saturating
the reticuloendothelial system (RES) by pretreatment with a
high dose of multilamellar vesicles (MLV), resulting in a tran-
sient decrease of hepatic uptake (30). It has also been shown
that pretreatment with reversed-phase evaporation vesicles
(REV) decreases liver uptake of a second dose of similar ves-
icles (31). Pretreatment with either REV or small unilamellar
vesicles (SUV) induces reticuloendothelial blockade, resulting
in slower blood clearance of liposomes (32). Pretreatment with
latex beads also increases the time that REV remain in the cir-
culation, but this approach does not have a significant effect on
uptake of vesicles by the liver (32). Proffitt et al. (33) have re-
ported that aminomannose-modified SUV cause RES blockade
in tumor-bearing mice and higher tumor uptake of SUV but
only modest reduction in the liver uptake.
Compounds that are toxic to liver macrophages have also been
used to block the liver uptake of liposomes. Tanaka et al. (34)
have used methyl palmitate, which is toxic to macrophages, and
Souhami et al. (35) have used dextran sulfate Mr 500,000 (DS),
known to be toxic to hepatic macrophages (36), for reticuloen-
dothelial blockade to alter tissue distribution of liposomes.
In this paper we report further studies of the use of DS to
reduce liver uptake of multilamellar liposomes. We have in-
vestigated: (i) the effect of various doses of intraperitoneally
(i.p.) injected DS on the tissue distribution of MLV; (ii) the length
of time of the effect of i.p. injected DS on the liver distribution
of MLV; (iii) the relative effectiveness of i.p. vs. i.v. injection
of DS; (iv) DS liver blockade in comparison with nontoxic MLV
liver blockade; and (v) the effect of a combination of two dif-
ferent liver blockade agents.
MATERIALS AND METHODS
L-a-Distearoyl phosphatidylcholine, stearylamine, cholesterol,
and DS sodium salt with Mr 500,000 were obtained from Sigma.
Deferoxamine mesylate (DF; Desferal) was purchased from CIBA
Pharmaceutical. Amersham/Searle was the source of radioac-
tive iron in the form of 59FeC13 in 0.1 M HCl (1 mCi/ml; 1 Ci
= 3.7 X 10'0 Bq). The mice used were 3-31/2-month-old fe-
male Swiss Webster obtained from Simonsen Laboratories (Gil-
roy, CA).
Preparation of Liposomes. Liposomes containing, in the
aqueous compartment, DF and a trace amount of 59Fe-labeled
DF (59Fe-DF) were prepared according to methods described
by Guilmette et al. (37). Distearoyl phosphatidylcholine, cho-
lesterol, and stearylamine in the molar ratio of 1.5:1:0.40 were
dried in a round-bottom flask. An aqueous phase containing 75
mg of 59Fe-DF per ml of water was typically added to 38 mg
of total lipids in the flask and stirred at 60'C for 10 min. Unen-
capsulated 59Fe-DF was removed by three successive centrif-
ugations at 3,015 X g for 10 min, each time resuspending the
pellet in 5-7 ml of phosphate-buffered saline (Pi/NaCl).
In Vivo Liver Blockade. DS in Pi/NaCl was injected either
i.p. or i.v., in dosages ranging from 10 to 50 mg/kg of body
weight. In the controls, only P1/NaCl was injected instead of
DS. Each group included four mice. For an experiment in which
a combination of liver-blocking agents was used, 50 mg of DS
Abbreviations: DS, dextran sulfate M. 500,000; MLV, multilamellar ves-
icle(s); SUV, small unilamellar vesicle(s); REV, reversed-phase evapo-
ration vesicle(s); i.v., intravenous(ly); i.p., intraperitoneal(ly); RES, re-
ticuloendothelial system; DF, deferoxamine; % ID, percent injected dose.
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FIG. 1. Uptake ofMLV as a function ofDS dosage (DS injected i.p. at hour 0; MLV injected i.v. at hour 24; sample taken at hour 26). Each value
represents the mean ± SEM of four mice.
per kg was injected by the i.p. route. After waiting 22 hr MLV
were then injected, 2 mg of lipid mixtures per mouse by the
i.v. route, followed by MLV with encapsulated 'Fe-DF by the
i.v. route at 24 hr.
Measurement of Tissue Uptake of Radioactivity. When the
mice were sacrificed, they were weighed and "% of injected
dose" (% ID) in various tissues was determined from the total
radioactivity injected into each mouse. Then the % ID per g in
each tissue was calculated with the assumption that blood com-
prises 7.3% of the total body weight of animals (38). Blood was
collected from the jugular vein and weighed, the radioactivity
was counted, and dose per g was calculated. The activity of each
tissue sample was determined with a Beckman Biogamma
counter.
RESULTS
Uptake of MLV as a Function of Dosage of DS. The effects
of increasing doses of DS as a liver-blocking agent are shown
in Fig. 1. In all uptake experiments shown in this figure, the
200
()
N
C3
100
0)
0
a. L~~~~~~~_ungj
DS was given i.p., followed 24 hr later by an i.v. injection of
MLV encapsulating radioactive deferoxamine (59Fe-DF). Two
hours later the tissues shown were taken for analysis of radio-
activity. As the DS dosage increased from 0 to 50 mg/kg of body
weight, spleen, lung, and tibia showed a large increase, whereas
liver showed a concomitant decrease. Other tissues (heart, small
intestine, kidney, brain, stomach, and large intestine) omitted
from the graph were measured only at the end points of the DS
concentration range and showed very small uptake compared
to lung, spleen, tibia, and liver. Fifty milligrams of DS per kg
appears to be about the maximal dose that can be tolerated
without significant lethality (39).
A full time-course experiment was conducted with 50 mg of
DS per kg of body weight given i.p., followed at a specified
interval by an i.v. injection of 59Fe-DF containing MLV, fol-
lowed 2 hr later by tissue analysis.
As shown in Fig. 2, the blockade effect peaked at different
times in different tissues. The full effect of the blockade ap-
peared in spleen, tibia, and liver in 6-12 hr and in lung in 24
hr and was negligible in blood. In all of the tissues that did show
Time between dextran sulfate injection and.MLV injection (hours)
FIG. 2. Uptake of MLV as a function of time between injection of DS and MLV injection (DS injected i.p., 50 mg/kg of body weight, at hour0; MLV injected i.v. at hours 2, 6, 12, etc.; sample taken 2 hr after MLV injection). Each value represents the mean + SEM of four mice.
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FIG. 3. Effect of DS injection,. 50 mg/kg of body weight, either by
i.p. or iv. route on the uptake ofMLV (DS injected at hour 0; MLV in-jected i.v. at hour 24; sample taken at hour 26)..Each value represents
the mean ± SEM of four mice.
an effect, the tissue activities were back to preblockade levels
by 48 hr after the DS injection.
The effect 24 hr after injection of i.v. DS on MLV uptake is
shown in Fig. 3. Spleen, tibia, and blood uptake of MLV in
mice that -had received DS by the i.v. route was similar to up-
take in mice that had received DS by the i.p. route. The effect
of DS injected by the i.v. route was lower lung uptake and higher
liver uptake of MLV compared to DS injected by the i.p. route.
Uptake of MLV as a Function of Time. Experiments were
then conducted with 50 mg of DS per kg of body weight given
i.p. (or omitted), followed by 59Fe-DF containing MLV in 24
hr, followed by tissue analysis of radioactivity in 1, 3, or 6 hr.
In the absence of DS injection the tissue distribution is quite
stable over the sampling range of 1-6 hr after MLV injection,
as shown in Fig. 4. In the presence of the DS, the tissue dis-
tribution over that sampling range is quite stable in the tibia,
liver, and blood, but it appears to increase gradually in spleen
and decrease gradually in lung. Actual MLV uptake values for
spleen,- lung, and tibia with DS injection were very high, at all
of the time points tested, compared to tissues in the absence
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of DS injection. The liver uptake of MLV in the DS-injected
mice was very low compared to liver in the absence of DS. Blood
circulation of MLV after DS injection increased -9, 4, and 3 times
at 1, 3, and 6 hr, respectively.
Uptake of MLV as a Function of Blockade Agent. In the
previous experiments, DS was used as the'blocking agent. An-
other blocking technique is to saturate the liver with MLV be-
fore administration of additional MLV expected to reach the
other tissues. As shown in Fig. 5, iv. injection of MLV (2 mg
of lipids per mouse) caused only moderate reduction in the liver
uptake with moderate increase in lung and tibia and a very large
increase in spleen uptake. However, i.p. injection of DS (50
mg/kg of body weight) was more effective in liver blockade,
resulting in very high lung, spleen, and tibia uptake. When both
MLV (2 mg of lipids per mouse) and DS (50 mg/kg of body
weight) were used in combination as blocking agents, no further
improvement in the liver blockade was observed.
DISCUSSION
We have tested the effect of DS, which has been reported to
be toxic to hepatic macrophages (36, 40), on the tissue uptake
and distribution of positively charged MLV. As the dose of DS
increased to 50 mg/kg of body weight, MLV uptake by liver
decreased. This reduction in the liver uptake of MLV made
liposomes available to other organs, such as tibia (bone mar-
row), lung, and spleen for higher uptake.
Because of the toxic nature of DS, we studied the length of
the suppression in the liver uptake. Our results show that the
uptake of MLV by liver drops as early as 2 hr after DS-injection.
Liver suppression due- to DS reached a maximum 12 hr after
DS injection. At 24 hr after DS injection, liver uptake was 70%
lower than control mice-but had started to recover. Forty-eight
hours after DS injection, liver uptake was similar to that in con-
trols, suggesting either the recovery of liver macrophages from
the DS toxicity or the replacement of damaged macrophages by
new cells.
Our results are in agreement with Souhami et al. (35), who
have shown that i.v. injection of 0.75 mg of DS per 20- to 30-
g mouse (30 mg/kg) 2 hr prior to neutral MLV reduced the liver
uptake by 35% at 30 min after injection. Their liver blockade
caused 95% increase in spleen and 36% increase-in lung uptake
of MLV. Our results demonstrate much higher effects than
Souhami et al. (35) reported on both the liver suppression as
well as increased uptake in bone marrow, spleen, and lung.
Even though DS is reported to be toxic to hepatic macro-
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FIG. 4. Uptake ofMLV as a function of time between MLV injection and tissue sampling (DS or Pi/NaCl injected i.p. at hour 0; MLV injected
iv. at hour 24; sample taken at hour 25, 27, or 30). Each value represents the mean ± SEM of four mice.
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FIG. 5. Uptake ofMLV as a function of liver blockade agent (DS or Pi/NaCl injected i.p. at hour 0; blocking unlabeled MLV or P1/NaCl in~jected
iLv. at hour 22; radioactive MLfV injected at hour 24; sample taken at hour 26; dosages: 50 mg of DS per kg of body weight; 2 mg of lipid mixtures
of MLV per mouse). Each value represents the mean ± SEM of four mice.
phages, our results suggest that such effects may be only tem-
porary, lasting <48 hr after injection. If the effects of DS are
tolerable, which seems to be the case in mice, it might be pos-
sible to improve significantly the therapy of lung tumor, lym-
phoma, or leukemia by encapsulating antitumor drugs in li-
posomes and injecting them after DS blockade. A second
application of liver suppression would be in the detection of
metastases in either lung or spleen by using vesicle-encapsu-
lated radioactive agents. Because of high liver uptake, the de-
tection of tumor or metastases in either lung or spleen by li-
posome-encapsulated radioactive agents is very difficult. Ra-
dioactivity taken up by liver increases the difficulty of imaging
either lung or spleen. This problem might be resolved by dras-
tic reduction in the liver uptake of liposomes with the use of
DS.
Our results also show that the RES can be blocked to a cer-
tain extent by iLv. injection of MLV. Injection of unlabeled MLV
prior to injection of radioactive MLV resulted in a 23% re-
duction in the liver uptake of the labeled liposomes. This mod-
erate drop in the liver uptake was accompanied by higher up-
take in tibia (bone marrow), lung, and spleen.
Our results are consistent with the work of Ellens et al. (31),
who have shown that i.v. injection of unlabeled REV 1 hr prior
to injection of radioactive REV reduced the liver uptake by 50%
and spleen uptake by 21%. Kao and Juliano (32) have used latex
beads as an agent to block the RES. After a 1-hr blockade with
latex beads, they injected REV by the i.v. route and followed
the tissue distribution 2 hr later. This approach had no effect
on liver uptake, but spleen uptake was decreased by 45%, and
substantially higher lung uptake was observed.
The amount of MLV circulating in the blood after DS in-
jection was about 9, 4, and 3 times higher at 1, 3, and 6 hr,
respectively. Ellens et al. (31) have observed an increase of 5
times in the blood level of REV when the RES is first blocked
with REV. Abra et al. (30) observed a 29 times higher blood
level of MLV at 1 hr after MLV blockade. This level was sharply
reduced after 6 hr. However, Abra et al. (30) filtered their MLV
through a 1-mm pore-size Nucleopore membrane. The smaller
MLV used in their experiments, compared to our unfiltered
MLV, could have caused their observed higher blood levels.
Our results suggest that DS is more effective in liver block-
ade than MLV and might be useful as a liver blockade agent,
allowing liposomes to accumulate in the spleen, lung, and bone
marrow. This approach could provide a significant opportunity
for tumor treatment as well as tumor diagnosis by radiolabel
imaging techniques.
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